H
Hangzhou Jianhai Technology
AI-powered platform for post-discharge disease and patient management
About Hangzhou Jianhai Technology
Hangzhou Jianhai Technology Co., Ltd., also known as Justhealth, is a digital health services company founded in 2015 by CEO Wang Jian. The company focuses on post-discharge patient and disease management, creating a closed loop of care that extends from the hospital to the community and home. Justhealth's core mission is to make "caring a good medicine."
The company offers an AI-powered, cloud-based platform that assists healthcare professionals with patient management. Its main products include the "AI Full-Course Management Platform" for hospitals, the "AI Graded Chronic Disease Diagnosis and Treatment Platform" for medical communities, and the "Smart Education 3.0 Health Education Platform" for patients. These systems use technologies such as deep learning, big data processing, and natural language processing to automate tasks like patient follow-up, satisfaction surveys, and appointment reminders, thereby reducing the workload of medical staff. The platform integrates with hospital information systems (HIS, LIS, PACS) to gather comprehensive patient data, which also supports clinical research.
Justhealth operates on a B2B business model, providing its software and services to hospitals. This is done in two ways: either by exporting its entire disease management system to a hospital for their own use, or by co-building and co-operating a post-discharge management center with the hospital. This model has allowed Justhealth to partner with over 1,000 hospitals, including prominent institutions like Shanghai Jiao Tong University's Ruijin Hospital, and achieve a market share of over 70% in the post-discharge disease management sector. Revenue is primarily generated through subscription-based models for its digital health services.
The company has secured significant funding, accumulating over 1 billion RMB across multiple rounds. Notable funding includes a 150 million RMB Series B round in March 2021, led by Sequoia Capital China, and a 500 million RMB ($78.1M) Series B+ round in November 2021, led by Huaxing New Economy Fund. Other prominent investors include Source Code Capital, Sherpa Healthcare Partners, and China Renaissance.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2021 | $69M | $275M | Sequoia | ↗ |
| SERIES BOther financing | Mar 2021 | $21M | $83M | Source Code Capital · Sherpa Venture Partners · Sequoia | ↗ |
Growth signals
Latest recorded traffic for Hangzhou Jianhai Technology is 640 monthly website visits, up 36.2% over the last three months. Hangzhou Jianhai Technology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hangzhou Jianhai Technology in the Hangzhou ecosystem
The Hangzhou Jianhai Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Sherpa Venture Partners
iFLYTEK- HCHaibang Capital
Source Code Capital
Sequoia
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hangzhou Jianhai Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hangzhou Jianhai Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










